Patient Identification for TEPEZZA

TEPEZZA demonstrated results in patients with varied clinical presentations of Thyroid Eye Disease (TED)1,2

See results for patients treated with TEPEZZA in clinical trials

Baseline proptosis front view Baseline proptosis front view Baseline proptosis front view

Baseline3

Proptosis: 24 mm

Diplopia: 0

Clinical Activity Score (CAS): 5

Inflammatory signs and symptoms

  • Eyelid swelling
  • Eyelid erythema
  • Conjunctival redness
  • Chemosis
  • Inflammation of caruncle/plica
Post-treatment with TEPEZZA proptosis front view Post-treatment with TEPEZZA proptosis front view Post-treatment with TEPEZZA proptosis front view

Post-Treatment (Week 24)3

Proptosis: 19 mm

Diplopia: 0

CAS: 1

Inflammatory signs and symptoms

  • Eyelid swelling
Front view of protruding eyes before treatment Front view of protruding eyes before treatment Front view of protruding eyes before treatment

Baseline4

Proptosis: 25 mm

Diplopia: 3

CAS: 5

Inflammatory signs and symptoms

  • Spontaneous orbital pain
  • Gaze-evoked orbital pain
  • Eyelid swelling
  • Eyelid erythema
  • Conjunctival redness
Front view of protruding eyes after TEPEZZA treatment Front view of protruding eyes after TEPEZZA treatment Front view of protruding eyes after TEPEZZA treatment

Post-Treatment (Week 24)4

Proptosis: 21 mm

Diplopia: 0

CAS: 0

Inflammatory signs and symptoms

  • No inflammatory signs and symptoms
Side view of bulging eyes before treatment Side view of bulging eyes before treatment Side view of bulging eyes before treatment

Baseline4

Proptosis: 25 mm

Diplopia: 3

CAS: 5

Inflammatory signs and symptoms

  • Spontaneous orbital pain
  • Gaze-evoked orbital pain
  • Eyelid swelling
  • Eyelid erythema
  • Conjunctival redness
Side view of bulging eyes after TEPEZZA treatment (Week 24) Side view of bulging eyes after TEPEZZA treatment (Week 24) Side view of bulging eyes after TEPEZZA treatment (Week 24)

Post-Treatment (Week 24)4

Proptosis: 21 mm

Diplopia: 0

CAS: 0

Inflammatory signs and symptoms

  • No inflammatory signs and symptoms

Patient treated with TEPEZZA in a clinical trial. Results shown are with no surgical intervention. Individual results may vary.

See results for patients with chronic TED treated with TEPEZZA

Front view of bulging eyes before treatment Front view of bulging eyes before treatment Front view of bulging eyes before treatment

Baseline2

Proptosis: 32 mm OD, 32.5 mm OS

Diplopia: 2

CAS: 3 OU

Front view of bulging eyes after TEPEZZA treatment Front view of bulging eyes after TEPEZZA treatment Front view of bulging eyes after TEPEZZA treatment

Post-Treatment2

Proptosis: 26 mm OD, 28 mm OS

Diplopia: 0

CAS: 0 OU

View from font and below of baseline proptosis before treatment View from font and below of baseline proptosis before treatment View from font and below of baseline proptosis before treatment

Baseline5

Proptosis: 25 mm

Diplopia: Not measured

CAS: 1

View from front and below of baseline proptosis post-treatment at week 34 (12 weeks after last infusion) View from front and below of baseline proptosis post-treatment at week 34 (12 weeks after last infusion) View from front and below of baseline proptosis post-treatment at week 34 (12 weeks after last infusion)

Post-Treatment (Week 34 [13 weeks after last infusion])5

Proptosis: 19 mm

Diplopia: Not measured

CAS: 0

Baseline left eye strabismus Baseline left eye strabismus Baseline left eye strabismus

Baseline5

Proptosis: 28 mm

Diplopia: Not measured

CAS: 0

Post-treatment strabismus improvement in left eye Post-treatment strabismus improvement in left eye Post-treatment strabismus improvement in left eye

Post-Treatment (8 Infusions)5

Proptosis: 21 mm

Diplopia: Not measured

CAS: 0

Front view of baseline proptosis and diplopia Front view of baseline proptosis and diplopia Front view of baseline proptosis and diplopia

Baseline6

Proptosis: 28 mm OD, 29 mm OS

Diplopia: 3

CAS: 4

Front view of post-treatment proptosis and diplopia Front view of post-treatment proptosis and diplopia Front view of post-treatment proptosis and diplopia

Post-Treatment (Week 104 [83 weeks after last infusion])6

Proptosis: 22 mm OD, 22 mm OS

Diplopia: 0

CAS: 0

Patient treated with TEPEZZA in a retrospective case series (N=31) of patients with chronic TED. Patient completed a full course of treatment with TEPEZZA (8 infusions)2.

Images from Ozzello DJ, Dallalzadeh LO, Liu CY. Teprotumumab for chronic thyroid eye disease. Orbit. 2021. Published online June 1, 2021. Reprinted with the permission of the publisher Informa UK Limited trading as Taylor & Francis Ltd.

Adapted with permission from Teprotumumab efficacy, safety, and durability in longer-duration Thyroid Eye Disease and re-treatment: OPTIC-X study.

Patient treated with TEPEZZA in a retrospective case series (N=9) of patients with chronic TED and low CAS. Patient completed a full course of treatment with TEPEZZA (8 infusions).5

Patient treated with TEPEZZA in OPTIC-X (N=51), an open-label (previous treatment-masked) TEPEZZA treatment and retreatment trial with patients from the randomized double-masked, multicenter, placebo-controlled Phase 3 OPTIC study. Patient received placebo in OPTIC and TEPEZZA in OPTIC-X and completed a full course of treatment with TEPEZZA (8 infusions).6

Proven safety icon Proven safety icon

Get your patients started on TEPEZZA

Learn more about prescribing TEPEZZA

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

Adverse Reactions

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, and menstrual disorders.

Please see Full Prescribing Information for more information.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

Adverse Reactions

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, and menstrual disorders.

Please see Full Prescribing Information for more information.

1. Diniz SB, Cohen LM, Roelofs KA, Rootman DB. Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast Reconstr Surg. 2021;37(6):583-591. 2. Ugradar S, Kang J, Kossler AL, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond). 2021. Published online July 9, 2021. doi:10.1038/s41433-021-01593-z. 3. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352. 4. Data on File. Horizon, January 2020. 5. Ozzello DJ, Dallalzadeh LO, Liu CY. Teprotumumab for chronic thyroid eye disease. Orbit. 2021:1-8. Published online June 1, 2021. doi:10.1080/01676830.2021.1933081. 6. Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety and durability in longer duration thyroid eye disease and retreatment: OPTIC-X study. Ophthalmology. Published online October 21, 2021. doi:10.1016/j.ophtha.2021.10.017